Prof Lalit Prakash Agarwal (1922-2004)—The Planner of the First-Ever National Blindness Control Program of the World
Ophthalmology and Eye Diseases · 2017
DOI: 10.1177/1179172117701742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology and Eye Diseases, 2017. Verfasst von Koushik Tripathy. Beteiligte Einrichtung: Department of Retina and Uvea, ICARE Eye Hospital & Postgraduate Institute, Noida, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Prof Lalit Prakash Agarwal drafted the National Programme for Prevention of Visual Impairment and Control of Blindness (now called National Programme for Control of Blindness) in India in 1976, first of its kind in the world. With his vision well ahead of his time, he brought the concept of super-specialty in Indian ophthalmology. He founded Dr. Rajendra Prasad Centre for Ophthalmic Sciences, the apex governmental ophthalmological center of India. His contributions to modern Indian Ophthalmology were so profound that we may not be mistaken by calling him “the father of modern Indian Ophthalmology.”
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Retina and Uvea, ICARE Eye Hospital & Postgraduate Institute, Noida, India.
Zitieren
APA
Tripathy, K. (2017). Prof Lalit Prakash Agarwal (1922-2004)—The Planner of the First-Ever National Blindness Control Program of the World. Ophthalmology and Eye Diseases. https://doi.org/10.1177/1179172117701742
Vancouver
Tripathy K. Prof Lalit Prakash Agarwal (1922-2004)—The Planner of the First-Ever National Blindness Control Program of the World. Ophthalmology and Eye Diseases. 2017. doi:10.1177/1179172117701742
BibTeX
@article{Tripathy2017,
author = {Tripathy, Koushik},
title = {Prof Lalit Prakash Agarwal (1922-2004)—The Planner of the First-Ever National Blindness Control Program of the World},
journal = {Ophthalmology and Eye Diseases},
year = {2017},
doi = {10.1177/1179172117701742}
}
EUVIMED